MX2015002062A - Formulaciones parenterales de rasagilina. - Google Patents

Formulaciones parenterales de rasagilina.

Info

Publication number
MX2015002062A
MX2015002062A MX2015002062A MX2015002062A MX2015002062A MX 2015002062 A MX2015002062 A MX 2015002062A MX 2015002062 A MX2015002062 A MX 2015002062A MX 2015002062 A MX2015002062 A MX 2015002062A MX 2015002062 A MX2015002062 A MX 2015002062A
Authority
MX
Mexico
Prior art keywords
rasagiline
subject
controlled release
release formulation
therapy
Prior art date
Application number
MX2015002062A
Other languages
English (en)
Spanish (es)
Inventor
Eran Blaugrund
Cheryl Fitzer-Attas
Rom E Eliaz
Aviva Gross
Adi Mayk
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of MX2015002062A publication Critical patent/MX2015002062A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
MX2015002062A 2012-08-17 2013-08-16 Formulaciones parenterales de rasagilina. MX2015002062A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261684530P 2012-08-17 2012-08-17
US201361775318P 2013-03-08 2013-03-08
PCT/US2013/055404 WO2014028868A1 (en) 2012-08-17 2013-08-16 Parenteral formulation of rasagiline

Publications (1)

Publication Number Publication Date
MX2015002062A true MX2015002062A (es) 2015-06-05

Family

ID=50100474

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015002062A MX2015002062A (es) 2012-08-17 2013-08-16 Formulaciones parenterales de rasagilina.

Country Status (10)

Country Link
US (1) US9308182B2 (enExample)
EP (1) EP2884972A4 (enExample)
JP (1) JP2015529196A (enExample)
AR (1) AR092168A1 (enExample)
BR (1) BR112015003451A2 (enExample)
CA (1) CA2882072A1 (enExample)
IL (1) IL237041A0 (enExample)
MX (1) MX2015002062A (enExample)
TW (1) TW201412304A (enExample)
WO (1) WO2014028868A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8946300B2 (en) 2006-04-03 2015-02-03 Teva Pharmaceutical Industries, Ltd. Use of rasagilline for the treatment of restless legs syndrome
EA201490761A1 (ru) 2011-10-10 2014-11-28 Тева Фармасьютикал Индастриз Лтд. R(+)-n-формилпропаргиламиноиндан
US9339469B2 (en) 2011-10-10 2016-05-17 Teva Pharmaceutical Industries, Ltd. R(+)-N-methyl-propargyl-aminoindan
EP2968222A4 (en) * 2013-03-13 2016-10-19 N To B Ltd METHOD, COMPOSITIONS AND DEVICES FOR TREATING MOTOR DISTURBANCES AND DEPRESSION SYMPTOMS RELATED TO MORBUS PARKINSON

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744500A (en) 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
IL92952A (en) 1990-01-03 1994-06-24 Teva Pharma R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
IL99759A (en) 1991-10-16 1997-06-10 Teva Pharma Mono-fluorinated derivatives of n-propargyl-1-aminoindan, their preparation and pharmaceutical compositions containing them
IL115357A (en) 1995-09-20 2000-01-31 Teva Pharma Stable compositions containing N-propargyl-1-aminoindan and polyhydric alcohols
IL118836A (en) 1996-07-11 2001-01-11 Teva Pharma Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan
ATE377585T1 (de) 1996-12-18 2007-11-15 Teva Pharma Aminoindanderivate
JP2002516295A (ja) * 1998-05-27 2002-06-04 アビジェン， インコーポレイテッド Ａａｖベクターの対流増加送達
US6670378B2 (en) * 2001-05-08 2003-12-30 Pharmacia & Upjohn Company Method of treating Parkinson's disease
US7396860B2 (en) 2002-11-15 2008-07-08 Teva Pharmaceutical Industries, Ltd. Use of rasagiline with or without riluzole to treat amyotrophic lateral sclerosis
EP1778196A4 (en) 2004-07-26 2008-12-17 Teva Pharma PHARMACEUTICAL DOSAGES CONTAINING RASAGILINE
ES2371883T3 (es) 2004-11-24 2012-01-11 Teva Pharmaceutical Industries Ltd. Composiciones de rasagilina de disgregación oral.
AU2006216696B2 (en) 2005-02-23 2011-08-18 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations of improved content uniformity
JP2009521402A (ja) 2005-11-17 2009-06-04 テバ ファーマシューティカル インダストリーズ リミティド プロパルギル化アミノインダンの分離のための方法
HUP0501084A2 (en) * 2005-11-23 2008-05-28 Richter Gedeon Nyrt New pharmaceutical compositions of high effectivity
US7572834B1 (en) 2005-12-06 2009-08-11 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations and processes for their preparation
EP1991214B1 (en) * 2006-02-21 2015-08-05 Teva Pharmaceutical Industries, Ltd. Use of rasagiline for the treatment of multiple system atrophy
CN101032474B (zh) * 2006-03-06 2011-02-16 重庆医药工业研究院有限责任公司 一种治疗或预防神经系统疾病的雷沙吉兰透皮贴片及其制备方法
US8946300B2 (en) * 2006-04-03 2015-02-03 Teva Pharmaceutical Industries, Ltd. Use of rasagilline for the treatment of restless legs syndrome
EP1892233A1 (de) 2006-08-18 2008-02-27 Ratiopharm GmbH Neue Salze des Wirkstoffs Rasagilin
US7547806B2 (en) 2006-12-14 2009-06-16 Teva Pharmaceutical Industries, Ltd. Tannate salt of rasagiline
ATE528989T1 (de) 2006-12-14 2011-11-15 Teva Pharma Kristalline feste rasagilin-base
EP1987816A1 (de) 2007-04-30 2008-11-05 Ratiopharm GmbH Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff
AU2008296908B2 (en) 2007-09-05 2014-01-09 Teva Pharmaceutical Industries, Ltd. Method of treating glaucoma using rasagiline
US8188149B2 (en) 2007-09-17 2012-05-29 Teva Pharmaceutical Industries, Ltd. Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss
NZ586025A (en) 2008-01-11 2012-08-31 Teva Pharma Rasagiline mesylate tablet coated with a composisiton comprising methacrylic acid - ethyl acrylate copolymer and triethyl citrate
WO2009151594A1 (en) 2008-06-10 2009-12-17 Teva Pharmaceutical Industries, Ltd. Rasagiline soft gelatin capsules
JP2011522892A (ja) 2008-06-13 2011-08-04 テバ ファーマシューティカル インダストリーズ リミティド パーキンソン病緩和のためのラサギリン
EP2299992A4 (en) 2008-06-19 2015-10-21 Teva Pharma PROCESS FOR THE PREPARATION AND DRYING OF A SOLID RASAGILINE BASE
JP2011525489A (ja) 2008-06-19 2011-09-22 テバ ファーマシューティカル インダストリーズ リミティド ラサリジン塩基の精製方法
DE102008064061A1 (de) 2008-12-19 2010-06-24 Ratiopharm Gmbh Feste Zusammensetzung mit dem Wirkstoff Rasagilin
US20100189788A1 (en) 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline base formulation
HRP20140845T1 (hr) 2009-07-09 2014-11-07 Ratiopharm Gmbh Soli rasagilina i farmaceutski pripravci od njih
US20110130466A1 (en) 2009-10-09 2011-06-02 Stefan Lorenzl Use of rasagiline for the treatment of progressive supranuclear palsy
EP2939669A1 (en) 2009-12-22 2015-11-04 Teva Pharmaceutical Industries, Ltd. 3-keto-n-propargyl-1-aminoindan
US9943489B2 (en) 2010-02-03 2018-04-17 Pharmatwob Ltd. Extended release formulations of rasagiline and uses thereof
RU2013108256A (ru) 2010-07-27 2014-09-10 Тева Фармасьютикал Индастриз Лтд. Дисперсии цитрата разагилина
RU2587330C2 (ru) 2010-07-27 2016-06-20 Тева Фармасьютикал Индастриз Лтд. Применение разагилина для лечения обонятельной дисфункции
CN103188933A (zh) 2010-10-26 2013-07-03 泰华制药工业有限公司 富集氘的雷沙吉兰
US9339469B2 (en) 2011-10-10 2016-05-17 Teva Pharmaceutical Industries, Ltd. R(+)-N-methyl-propargyl-aminoindan
EA201490761A1 (ru) 2011-10-10 2014-11-28 Тева Фармасьютикал Индастриз Лтд. R(+)-n-формилпропаргиламиноиндан
WO2013055684A1 (en) 2011-10-10 2013-04-18 Teva Pharmaceutical Industries Ltd. Rasagiline citramide

Also Published As

Publication number Publication date
EP2884972A4 (en) 2016-05-11
AR092168A1 (es) 2015-03-25
IL237041A0 (en) 2015-03-31
BR112015003451A2 (pt) 2017-07-04
CA2882072A1 (en) 2014-02-20
EP2884972A1 (en) 2015-06-24
US9308182B2 (en) 2016-04-12
JP2015529196A (ja) 2015-10-05
TW201412304A (zh) 2014-04-01
US20140051767A1 (en) 2014-02-20
WO2014028868A1 (en) 2014-02-20

Similar Documents

Publication Publication Date Title
DK168514B1 (da) Synergistisk produkt indeholdende en kombination af amantadin og selegilin, fremgangsmåde til fremstilling af produktet og anvendelse af amantadin og selegilin til fremstilling af produktet
CN102573823B (zh) 包含反式去甲舍曲林和血清素受体1a激动剂/拮抗剂的组合物及其用途
JP2006503918A5 (enExample)
US20080096872A1 (en) Composition for Treatment of Pain Specification
JP2006503918A (ja) ミルナシプランの改変放出組成物
KR20120101456A (ko) 중추 매개의 오심 및 구토를 치료하기 위한 조성물 및 방법
US20240148756A1 (en) Use of neuroactive steroid for treatment of sexual dysfunction
ZA200309048B (en) Pharmaceutical formulation for the efficient administration of apomorphine, 6aR-(-)-N-propyl-norapomorphine and their derivatives and pro-drugs thereof.
US9308182B2 (en) Parenteral formulations of rasagiline
WO2009015561A1 (en) The use of leonurine and compositions thereof
US20060110333A1 (en) Composition for nasal absorption
JP2002534379A (ja) 新規なブレチリウム組成物およびキットならびに心血管症状の予防および治療におけるそれらの使用
JP2015529196A5 (enExample)
US20110263659A1 (en) Analogs of 1-Methylnicotinamide
US20220193075A1 (en) Therapeutic drug for dyskinesia
WO2007040535A1 (en) Use of polyamine analogs for treatment and prevention of intestinal polyps
TW200846002A (en) Novel prophylactic and/or therapeutic agent for diabetic neuropathy
WO2023112024A1 (en) Method of treating parkinson's disease
CN117180245A (zh) 辅酶q10组合物及其制备工艺和在保护心脏中的应用
CN110402142A (zh) 含局麻药的酸性乳液组合物
CN113975276A (zh) 考比替尼在制备治疗缺血/再灌注损伤药物及细胞保护药物中的应用
CN114080221B (zh) 用于减轻疼痛的布洛芬与曲马多的组合
EP2658540A1 (en) Therapeutic use of dimiracetam to prevent the hand&foot syndrome caused by sorafenib
CN114761017B (zh) 用于疼痛疾患的米氮平和替扎尼定组合
CN117243947A (zh) 瑞香素及包含其的组合在制备糖尿病并发症药物中的应用